PharmaState Is Official Media Partner For DUPHAT 2022. Click the banner to explore more...spot_imgspot_imgspot_img

Top 10 Prescription Drugs 2021

-

 

This year Xarelto, a drug made by Bayer and J & J, was in 10th position. Till now, this Factor Xa Inhibitor pharmacological product sales was of worth $7605 million.

BTK inhibitor pharmacological class product – Imbruvica ranked 9th position. AbbVie, a maker of this drug, made $7607 million from this drug.

HIV INSTI/ NRTI/ NRTI pharmacological class drug –Biktarvy held 8th position in 2021. Gilead Sciences made around $8418 million worth of sales from this product.

J & J and Mitsubishi Chemical Anti – IL12/IL23 mAb pharmacological class product named Stelara ranked 7th positions. This year, a totals sale was around $8445 million.

Opdivo, an Anti-PD1mAb product, was in 6th position. Bristol Myers Squibb and Ono Pharm were the makers of this product. With this drug, both companies achieved sales of around $8759 million at this moment.

Eylea, an Anti-VEGF mAb pharmacological class product, had secured 5th position. This drug was the combined effort of Regeneron, Bayer and Santel Pharmaceutical. This year from this drug, total sales of $8872 million it brought.

Eliquis, a Factor Xa Inhibitor product, ranked 4th position. Bristol-Myers, Bayer-Squibb and Pfizer were the producers of this drug. $10546 million of sales were made from this drug till now.

An Immunomodulator pharmacological class product named Revlimid held 3rd rank. Bristol-Myers and Bayer-Squibb were the drug makers and around $12710 million of sales this drug brought.

Merck’s Keytruda – Anti-PD 1 mAb product was in 2nd rank. In 2021, the total sale was $16825 million as of now.

Humira, an Anti-TNF mAb product of AbbVie/Eisai, ranked 1st position. Till now, the total sale was $19963 million.

 

 

 

PharmaState Blog
This is a platform for people working in the pharmaceuticals industry for Discussions, Jobs, News updates, Professional Profile display space and company business pages. PharmaState DNA is having four pillars: Quality, Transparency, Innovation & Benchmarks.

Share this article

Recent posts

Popular categories

Leave a Reply

Recent comments

Business Alnavedic on History of Indian Pharma Industry
Ahmed Mohamed Elkhodragy on MACO Calculation
Jennifer Osunde on DEFECTS IN UNCOATED TABLETS
Vinod on DEVIATION
Rajib ghose on TOOLING FOR TABLETING
K. SRinivasula Reddy on Quality Agreements – PART 2
Sunil Kumar M on SITE ACCEPTANCE TEST (SAT)
Khalid on IQ Protocol
Khalid on IQ Protocol
Nagabooshanam on Calibration of Reactor
PharmaState Blog on SOP for Sampling
Swapnil Khodake on TOOLING FOR TABLETING
%d bloggers like this: